TargetIntegrin alpha-V/beta-5(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 7.80nMAssay Description:Inhibitory concentration for human vitronectin binding to immobilized alphaV-beta5 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-5(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 8.70nMAssay Description:Inhibitory concentration for human vitronectin binding to immobilized alphaV-beta5 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-5(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+3nMAssay Description:Inhibitory concentration for human vitronectin binding to immobilized alphaV-beta5 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-5(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+3nMAssay Description:Inhibitory concentration for human vitronectin binding to immobilized alphaV-beta5 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-5(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 2.20E+3nMAssay Description:Inhibitory concentration for human vitronectin binding to immobilized alphaV-beta5 integrinMore data for this Ligand-Target Pair